AlbionVentures

23 November 2011

Mirada Medical Software Selected for Tumor Metrics at MD Anderson Cancer Center

Mirada Medical announced that it has been selected to deliver its advanced XD3 image review and analysis software to The University of Texas MD Anderson Cancer Center in Houston. Mirada's latest XD3 software release includes volumetric CT segmentation in addition to tools for CT/PET and MR/PET to facilitate both anatomical and functional response tracking. Mirada XD3 provides powerful tools and efficient workflows for quantification and tracking of findings in an unlimited number of studies for all major modalities including CT, MR, CT/PET and MR/PET.

"We are delighted that MD Anderson Cancer Center has chosen Mirada software." stated Dr. Timor Kadir, Chief Scientist at Mirada Medical. "With tools such as CT segmentation, auto-alignment, and built-in findings tracking, our latest release offers the power to handle the growing imaging volumes and complexity in trials."

Return to portfolio

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 

 

MAY 2009,

ALBION VENTURES INVESTS £1.5 MILLION IN AN MBO OF MIRADA MEDICAL FROM SIEMENS

London, Albion Ventures LLP (formerly Close Ventures*) announces that it is investing £1.5 million into medical software company Mirada Medical to fund its MBO from Siemens. Mirada has developed software that allows medical images from multiple sources to provide greater clinical accuracy in diagnosis and treatment of medical conditions. Currently, scanning from MRI, CT or PET has specific advantages and disadvantages when imaging certain parts of the body. MRI is good at imaging organs and soft issues but less good at viewing tumours and bones, which a CT scan can show. Mirada’s software enables images from to be fused together to show, for instance, not only where a cancer is, but also where it is relative to other organs or how rapidly it is developing. Fusing images provides surgeons or radiographers with a complete picture of internal structures increasing their ability to successfully treat conditions. Mirada is the third medical scanning firm that Albion Ventures has invested in following Dexela, which produces and 3D mammograms and Forth Photoincs that has developed technology that enhances diagnosis and treatment of cervical cancer. David Gudgin, Partner, Albion Ventures, said: “Healthcare is a focus of investment for us. Mirada as out third medical scanning investment demonstrates the advantages of the sector. All three companies operate in the high growth area of medical imaging in different clinical areas using differing technologies. We believe this MBO is an attractive opportunity to re-establish Mirada Medical an a leading force in molecular imaging. Hugh Bettesworth Chief Executive, said: “The team at Albion Ventures demonstrated an excellent working knowledge of the healthcare sector. As a stand alone company if gives us great confidence to know that our investors genuinely understand our business and so can add real value through their experience and commitment to hands on support.” *Albion Ventures LLP is a partnership formed by the Close Ventures management team in January 2009 when it acquired the business of Close Ventures from Close Brothers Group plc.

Return to portfolio